Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151125 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of IL-11 (Neumega) in Von Willebrand Disease
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00151125 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 12 participants.
The verdict
NCT00151125, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study is testing the use of rhIL-11 (recombinant interleukin 11, Neumega) in individuals with Von Willebrand disease. The purpose is to evaluate: 1. if rhIL-11 corrects VWF (Von Willebrand Factor) levels to normal 2. if rhIL-11 and DDAVP together will boost VWF levels even higher 3. the onset, peak, and duration of rhIL-11 effect 4. if rhIL-11 is safe in individuals with Von Willebrand Disease
Interventions
- DRUG recombinant interleukin-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-07 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151125
The ClinicalTrials.gov registry entry for NCT00151125 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which recombinant interleukin-11 is the first listed.
NCT00151125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00151125 about?
NCT00151125 is a clinical study titled "Phase II Study of IL-11 (Neumega) in Von Willebrand Disease". This study is testing the use of rhIL-11 (recombinant interleukin 11, Neumega) in individuals with Von Willebrand disease. The purpose is to evaluate: 1. if rhIL-11 corrects VWF (Von Willebrand Factor) levels to normal 2. if rhIL-11 and DDAVP together will boost VWF levels even higher 3. the onset,...
What is the current status of trial NCT00151125?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2004-07. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00151125?
The interventions under investigation include: recombinant interleukin-11 (DRUG).
Who is sponsoring clinical trial NCT00151125?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.